bioRxivImmunology
Distinct Single-cell Immune Ecosystems Distinguish True and De Novo HBV-related Hepatocellular Carcinoma Recurrences
S. Chen, C. Huang, G. Liao, H. Sun, Y. Xie, J. Wang, M. He, H. Hu, Z. Dai, X. Ren, X. Zeng, Q. Zeng, G. Zhang, C. Liao, W. Xie, S. Shen, S. Li, S. Peng, D. Kuang, Q. Zhao, D. Duda, M. Kuang
Abstract
Revealing differential tumor immune microenvironment (TIME) characteristics between true versus de novo hepatocellular carcinoma (HCC) recurrence could help optimal development and use of immunotherapies. Here, we studied the TIME of recurrent HBV-related HCCs by 5and VDJ single-cell and bulk RNA-sequencing, flow cytometry, and multiplexed immunofluorescence. Analyses of mutational profiles, evolutionary trajectories, and clonal architecture using whole-exome sequencing identified de novo versus true recurrences, some of which occurred before clinical diagnosis. The TIME of truly recurrent HCCs was characterized by an increased abundance in KLRB1+CD8+ T cells with memory phenotype and low cytotoxicity. In contrast, we found an enrichment in cytotoxic and exhausted CD8+ T cells in the TIME of de novo recurrent HCCs. Transcriptomic and interaction analyses showed an upregulated GDF15 expression level on HCC cells in proximity to dendritic cells, which may have dampened antigen presentation and inhibited anti-tumor immunity in the TIME of truly recurrent lesions. In contrast, we found that myeloid cells crosstalk with T cells mediated T cell exhaustion and immunosuppression in the TIME of de novo recurrent HCC. In conclusion, our results support genomic diagnosis and immune profiling for guiding immunotherapy implementation based on the type of HCC recurrence and TIME. HighlightsO_LITruly recurrent lesions are seeded before primary tumor diagnosis, and that de novo cancer can occur earlier than the clinically used 2-year limit. C_LIO_LIScRNA-seq unravels distinct immune ecosystems in true versus de novo HCC recurrences, highlighting the need for different immunotherapy strategies for two types of HCC recurrence. C_LIO_LICD8+ T cells in de novo recurrence displayed cytotoxic and exhausted phenotypes while those in truly recurrent lesions showed a memory phenotype with weak cytotoxicity. C_LIO_LIHCC cells expressing the inhibitory molecule GDF15 were in the proximity of DCs only in truly recurrent lesions. C_LIO_LIHigh GDF15 expression level was associated with truly recurrent HCC and worse prognosis. C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=186 SRC="FIGDIR/small/494526v1_ufig1.gif" ALT="Figure 1"> View larger version (71K): org.highwire.dtl.DTLVardef@1b76bf0org.highwire.dtl.DTLVardef@10f889aorg.highwire.dtl.DTLVardef@d16b52org.highwire.dtl.DTLVardef@dceb7a_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: scRNA-seq
- assay: bulk RNA-seq
- assay: flow cytometry
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell-cell communication
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hepatitis Viruses affect the expression of Endogenous Retrovirus and Tumor Microenvironment in HCC
Wei Zhang, Xiaoyang Wan·bioRxiv·Jun 19, 2022
- Accessing the specific capacity of TIL-derived CD8 T-cells to suppress tumor recurrence in resectable HBV-HCC patients
Janine Kah, Lisa Staffeldt, … Stefan Lüth·bioRxiv·Dec 5, 2024
- Single-cell analysis reveals distinct immune characteristics of hepatocellular carcinoma in HBV-positive versus HBV-negative cases
K. Liu, Erbao Chen, … Hongchang Li·bioRxiv·Dec 30, 2024
- Single-Cell RNA-Seq Reveals Naïve B cells Associated with Better Prognosis of HCC
- TIGIT-NECTIN2/3 signaling preserves ignorant CD8⁺ T cells for favorable immune checkpoint outcomes in HBV-related hepatocellular carcinoma
Pei-Ching Chang, Zhi-Chen Yan, … Yan‐Hwa Wu Lee·bioRxiv·May 8, 2026
- Ex-vivo expansion of patient-derived PBMCs preferentially results in effector memory T-cell proliferation with restored autologous efficiency in HBV-HCC
Janine Kah, Lisa Staffeldt, … Stefan Lüth·bioRxiv·Dec 1, 2024